{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:42:33Z","timestamp":1788370953575,"version":"build-2803163510"},"reference-count":113,"publisher":"Bentham Science Publishers Ltd.","issue":"29","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,9,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Thyroid cancer is the most common endocrine malignancy and it accounts for 1% of all\nnewly diagnosed tumors. Approximately 10% of patients with differentiated thyroid carcinomas (DTC)\nand 30% with medullary thyroid carcinoma (MTC) could not be cured with locoregional treatment and\ncould develop metastatic disease. In addition, one of the most aggressive solid tumors can arise from\nthe thyroid gland, the anaplastic thyroid carcinoma, with a median overall survival of less than 6\nmonths. Currently, only four drugs are approved for the treatment of DTC and MTC and several unmet\nneeds are focusing the scientific discussions, including the resistant setting, the off-target side effects\nthat may reduce the efficacy and the molecular knowledge-based combinations. In this review, we\naimed to discuss the current molecular landscape and treatment of thyroid cancers, and the ongoing\nclinical and translational research lines focusing on new drugs and drug combinations to improve the\ninhibition of driver mutations, such as BRAF and RET, and how systemic therapies that improved outcomes\nof other cancer types, like immunotherapy and peptide receptor radionuclide therapy, may play a\nrole in the future management of advanced thyroid cancers.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327666200214125712","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T13:26:06Z","timestamp":1581686766000},"page":"4806-4822","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Clinical and Translational Challenges in Thyroid Cancer"],"prefix":"10.2174","volume":"27","author":[{"given":"Jorge","family":"Hernando","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d\u00b4Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Pg Vall d\u00b4Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ros","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d\u00b4Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Pg Vall d\u00b4Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Arroyo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d\u00b4Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Pg Vall d\u00b4Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Gastrointestinal and Endocrine Tumor Unit, Vall d\u00b4Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Pg Vall d\u00b4Hebron 119-129, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1002\/cncr.24416","volume":"115","author":"Chen A.Y.","year":"2009","unstructured":"Chen A.Y.; Jemal A.; Ward E.M.; Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009,115(16),3801-3807","journal-title":"Cancer"},{"key":"ref=2","volume":"Vol. 10","author":"Lloyd R.D.","year":"2017","unstructured":"Lloyd R.D.; Osamura R.V.; Kl\u00f6ppel G.;  WHO Classifiation of Tumors of Endocrine Organs 2017,Vol. 10","journal-title":"WHO Classifiation of Tumors of Endocrine Organs"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12022-016-9445-4","volume":"27","author":"Xu B.","year":"2016","unstructured":"Xu B.; Ghossein R.; Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma. Endocr Pathol 2016,27(3),205-212","journal-title":"Endocr Pathol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s12094-016-1554-5","volume":"19","author":"Capdevila J.","year":"2017","unstructured":"Capdevila J.; Galofr\u00e9 J.C.; Grande E.; Zaf\u00f3n Llopis C.; Ram\u00f3n Y.; Cajal Asensio, T.; Navarro Gonz\u00e1lez, E.; Jim\u00e9nez-Fonseca, P.; Santamar\u00eda Sandi, J.; G\u00f3mez S\u00e1ez, J.M.; Riesco Eizaguirre, G. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI). Clin Transl Oncol 2017,19(3),279-287","journal-title":"Clin Transl Oncol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014,159(3),676-690","journal-title":"Cell"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1385\/EP:16:3:163","volume":"16","author":"Ciampi R.","year":"2005","unstructured":"Ciampi R.; Nikiforov Y.E.; Alterations of the BRAF gene in thyroid tumors. Endocr Pathol 2005,16(3),163-172","journal-title":"Endocr Pathol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1677\/erc.1.0978","volume":"12","author":"Xing M.","year":"2005","unstructured":"Xing M.; BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005,12(2),245-262","journal-title":"Endocr Relat Cancer"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1210\/jc.2005-0987","volume":"90","author":"Xing M.","year":"2005","unstructured":"Xing M.; Westra W.H.; Tufano R.P.; Cohen Y.; Rosenbaum E.; Rhoden K.J.; Carson K.A.; Vasko V.; Larin A.; Tallini G.; Tolaney S.; Holt E.H.; Hui P.; Umbricht C.B.; Basaria S.; Ewertz M.; Tufaro A.P.; Califano J.A.; Ringel M.D.; Zeiger M.A.; Sidransky D.; Ladenson P.W.; BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005,90(12),6373-6379","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=9","first-page":"565","volume":"5","author":"Suarez H.G.","year":"1990","unstructured":"Suarez H.G.; du Villard J.A.; Severino M.; Caillou B.; Schlumberger M.; Tubiana M.; Parmentier C.; Monier R.; Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990,5(4),565-570","journal-title":"Oncogene"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1309\/ND8D9LAJTRCTG6QD","volume":"120","author":"Zhu Z.","year":"2003","unstructured":"Zhu Z.; Gandhi M.; Nikiforova M.N.; Fischer A.H.; Nikiforov Y.E.; Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 2003,120(1),71-77","journal-title":"Am J Clin Pathol"},{"key":"ref=11","first-page":"2690","volume":"51","author":"Shi Y.F.","year":"1991","unstructured":"Shi Y.F.; Zou M.J.; Schmidt H.; Juhasz F.; Stensky V.; Robb D.; Farid N.R.; High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res 1991,51(10),2690-2693","journal-title":"Cancer Res"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"E1852","DOI":"10.1210\/jc.2013-2292","volume":"98","author":"Nikiforova M.N.","year":"2013","unstructured":"Nikiforova M.N.; Wald A.I.; Roy S.; Durso M.B.; Nikiforov Y.E.; Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 2013,98(11),E1852-E1860","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00125480-200111000-00005","volume":"8","author":"Tallini G.","year":"2001","unstructured":"Tallini G.; Asa S.L.; RET oncogene activation in papillary thyroid carcinoma. Adv Anat Pathol 2001,8(6),345-354","journal-title":"Adv Anat Pathol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"9875","DOI":"10.18632\/oncotarget.23986","volume":"9","author":"Romei C.","year":"2018","unstructured":"Romei C.; Ciampi R.; Casella F.; Tacito A.; Torregrossa L.; Ugolini C.; Basolo F.; Materazzi G.; Vitti P.; Elisei R.; RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases. Oncotarget 2018,9(11),9875-9884","journal-title":"Oncotarget"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1210\/en.2006-0926","volume":"148","author":"Reddi H.V.","year":"2007","unstructured":"Reddi H.V.; McIver B.; Grebe S.K.; Eberhardt N.L.; The paired box-8\/peroxisome proliferator-activated receptor-gamma oncogene in thyroid tumorigenesis. Endocrinology 2007,148(3),932-935","journal-title":"Endocrinology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1530\/ERC-13-0210","volume":"20","author":"Liu X.","year":"2013","unstructured":"Liu X.; Bishop J.; Shan Y.; Pai S.; Liu D.; Murugan A.K.; Sun H.; El-Naggar A.K.; Xing M.; Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer 2013,20(4),603-610","journal-title":"Endocr Relat Cancer"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"E1562","DOI":"10.1210\/jc.2013-2383","volume":"98","author":"Landa I.","year":"2013","unstructured":"Landa I.; Ganly I.; Chan T.A.; Mitsutake N.; Matsuse M.; Ibrahimpasic T.; Ghossein R.A.; Fagin J.A.; Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013,98(9),E1562-E1566","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/thy.2010.1646","volume":"20","author":"Xing M.","year":"2010","unstructured":"Xing M.; Genetic alterations in the phosphatidylinositol-3 kinase\/Akt pathway in thyroid cancer. Thyroid 2010,20(7),697-706","journal-title":"Thyroid"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"Levine A.J.","year":"2009","unstructured":"Levine A.J.; Oren M.; The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009,9(10),749-758","journal-title":"Nat Rev Cancer"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"Brose M.S.","year":"2014","unstructured":"Brose M.S.; Nutting C.M.; Jarzab B.; Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial. Lancer 2014,384(9940),319-328","journal-title":"Lancer"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1200\/JCO.2017.35.15_suppl.6083","volume":"35","author":"Jaume Capdevil","year":"2017","unstructured":"Jaume Capdevil; Ignacio Matos Garcia; Francesco M Mancuso, Carmela Iglesias, Paolo Nuciforo, Carles Zafon, Hector G. Palmer, Zighereda Ogbah, Laura Mui\u00f1os, Carol Elaine Pena, Marcia S. Brose, Martin Schlumberger, Ana Vivancos. RNAseq analysis of the sorafenib phase III DECISION trial in differentiated thyroid cancer (DTC): Correlation with clinical outcome. J Clin Oncol 2017,35(15_suppl),6083-6083","journal-title":"J Clin Oncol"},{"key":"ref=22","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx368.005","volume":"28","author":"Matos I","year":"2017","unstructured":"Matos I; Mancuso F; Iglesias C.; Prognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC). Ann Oncol 2017,28(Issue suppl_5)","journal-title":"Ann Oncol"},{"key":"ref=23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.6089","volume":"36","author":"Bowles DW","year":"2018","unstructured":"Bowles DW; Ross JS; Gay LM; Comprehensive genomic profiling of anaplastic thyroid carcinoma. J Clin Oncol 2018,36(suppl;abstr 6089)","journal-title":"J Clin Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1093\/annonc\/mdy123","volume":"29","author":"Capdevila J.","year":"2018","unstructured":"Capdevila J.; Mayor R.; Mancuso F.M.; Iglesias C.; Carat\u00f9 G.; Matos I.; Zaf\u00f3n C.; Hernando J.; Petit A.; Nuciforo P.; Cameselle-Teijeiro J.M.; \u00c1lvarez C.; Recio J.A.; Tabernero J.; Matias-Guiu X.; Vivancos A.; Seoane J.; Early evolutionary divergence between papillary and anaplastic thyroid cancers. Ann Oncol 2018,29(6),1454-1460","journal-title":"Ann Oncol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"Schlumberger M.","year":"2015","unstructured":"Schlumberger M.; Tahara M.; Wirth L.J.; Robinson B.; Brose M.S.; Elisei R.; Habra M.A.; Newbold K.; Shah M.H.; Hoff A.O.; Gianoukakis A.G.; Kiyota N.; Taylor M.H.; Kim S.B.; Krzyzanowska M.K.; Dutcus C.E.; de las Heras B.; Zhu J.; Sherman S.I.; Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015,372(7),621-630","journal-title":"N Engl J Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"Wells S.A.","year":"2012","unstructured":"Wells S.A.; Robinson B.G.; Gagel R.F.; Dralle H.; Fagin J.A.; Santoro M.; Baudin E.; Elisei R.; Jarzab B.; Vasselli J.R.; Read J.; Langmuir P.; Ryan A.J.; Schlumberger M.J.; Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012,30(2),134-141","journal-title":"J Clin Oncol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"Elisei R.","year":"2013","unstructured":"Elisei R.; Schlumberger M.J.; M\u00fcller S.P.; Sch\u00f6ffski P.; Brose M.S.; Shah M.H.; Licitra L.; Jarzab B.; Medvedev V.; Kreissl M.C.; Niederle B.; Cohen E.E.; Wirth L.J.; Ali H.; Hessel C.; Yaron Y.; Ball D.; Nelkin B.; Sherman S.I.; Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013,31(29),3639-3646","journal-title":"J Clin Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","volume":"26","author":"Cohen E.E.","year":"2008","unstructured":"Cohen E.E.; Rosen L.S.; Vokes E.E.; Kies M.S.; Forastiere A.A.; Worden F.P.; Kane M.A.; Sherman E.; Kim S.; Bycott P.; Tortorici M.; Shalinsky D.R.; Liau K.F.; Cohen R.B.; Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008,26(29),4708-4713","journal-title":"J Clin Oncol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1056\/NEJMoa075853","volume":"359","author":"Sherman S.I.","year":"2008","unstructured":"Sherman S.I.; Wirth L.J.; Droz J.P.; Hofmann M.; Bastholt L.; Martins R.G.; Licitra L.; Eschenberg M.J.; Sun Y.N.; Juan T.; Stepan D.E.; Schlumberger M.J.; Motesanib Thyroid Cancer Study Group. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008,359(1),31-42","journal-title":"N Engl J Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-10-0994","volume":"16","author":"Carr L.L.","year":"2010","unstructured":"Carr L.L.; Mankoff D.A.; Goulart B.H.; Eaton K.D.; Capell P.T.; Kell E.M.; Bauman J.E.; Martins R.G.; Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010,16(21),5260-5268","journal-title":"Clin Cancer Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2017.01.029","volume":"76","author":"Ravaud A.","year":"2017","unstructured":"Ravaud A.; de la Fouchardi\u00e8re C.; Caron P.; Doussau A.; Do Cao C.; Asselineau J.; Rodien P.; Pouessel D.; Nicolli-Sire P.; Klein M.; Bournaud-Salinas C.; Wemeau J.L.; Gimbert A.; Picat M.Q.; Pedenon D.; Digue L.; Daste A.; Catargi B.; Delord J.P.; A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer 2017,76,110-117","journal-title":"Eur J Cancer"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","volume":"11","author":"Bible K.C.","year":"2010","unstructured":"Bible K.C.; Suman V.J.; Molina J.R.; Smallridge R.C.; Maples W.J.; Menefee M.E.; Rubin J.; Sideras K.; Morris J.C.; McIver B.; Burton J.K.; Webster K.P.; Bieber C.; Traynor A.M.; Flynn P.J.; Goh B.C.; Tang H.; Ivy S.P.; Erlichman C.; Endocrine Malignancies Disease Oriented Group. Mayo Clinic Cancer Center; Mayo Phase 2 Consortium. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010,11(10),962-972","journal-title":"Lancet Oncol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1210\/jc.2013-3713","volume":"99","author":"Bible K.C.","year":"2014","unstructured":"Bible K.C.; Suman V.J.; Molina J.R.; Smallridge R.C.; Maples W.J.; Menefee M.E.; Rubin J.; Karlin N.; Sideras K.; Morris J.C.; McIver B.; Hay I.; Fatourechi V.; Burton J.K.; Webster K.P.; Bieber C.; Traynor A.M.; Flynn P.J.; Cher Goh B.; Isham C.R.; Harris P.; Erlichman C.; Endocrine Malignancies Disease Oriented Group. Mayo Clinic Cancer Center, and the Mayo Phase 2 Consortium. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 2014,99(5),1687-1693","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.ejca.2015.05.020","volume":"51","author":"Lim S.M.","year":"2015","unstructured":"Lim S.M.; Chung W.Y.; Nam K.H.; Kang S.W.; Lim J.Y.; Kim H.G.; Shin S.H.; Sun J.M.; Kim S.G.; Kim J.H.; Kang C.W.; Kim H.R.; Cho B.C.; An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. Eur J Cancer 2015,51(12),1588-1595","journal-title":"Eur J Cancer"},{"key":"ref=35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.6021","volume":"36","author":"Schlumberger M","year":"2018","unstructured":"Schlumberger M; Newbold K; Hasan B; A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (CTD) progressing after first line therapy: EORTC 1209. J Clin Oncol 2018,36(suppl; abstr 6021)","journal-title":"J Clin Oncol"},{"key":"ref=36","volume":"36","author":"Brose MS","year":"2018","unstructured":"Brose MS; Shenoy S; Bhat N; A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting. J Clin Oncol 2018,36(suppl; abstr 6088)","journal-title":"J Clin Oncol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1200\/JCO.2017.73.0226","volume":"35","author":"Cabanillas M.E.","year":"2017","unstructured":"Cabanillas M.E.; de Souza J.A.; Geyer S.; Wirth L.J.; Menefee M.E.; Liu S.V.; Shah K.; Wright J.; Shah M.H.; Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: Results of a multicenter phase II international thyroid oncology group trial. J Clin Oncol 2017,35(29),3315-3321","journal-title":"J Clin Oncol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1158\/1078-0432.CCR-15-1127","volume":"22","author":"Schlumberger M.","year":"2016","unstructured":"Schlumberger M.; Jarzab B.; Cabanillas M.E.; Robinson B.; Pacini F.; Ball D.W.; McCaffrey J.; Newbold K.; Allison R.; Martins R.G.; Licitra L.F.; Shah M.H.; Bodenner D.; Elisei R.; Burmeister L.; Funahashi Y.; Ren M.; O\u2019Brien J.P.; Sherman S.I.; A phase II trial of the multitarget thyrosine kinase inhibitor Lenvatinib (E7080) in advanced medullary thyroid cancer. Clin Cancer Res 2016,22(1),44-53","journal-title":"Clin Cancer Res"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1089\/thy.2016.0621","volume":"27","author":"Ito Y.","year":"2017","unstructured":"Ito Y.; Onoda N.; Ito, KI Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid 2017,27(9),1142-1148","journal-title":"Thyroid"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2017.00025","volume":"7","author":"Tahara M.","year":"2017","unstructured":"Tahara M.; Kiyota N.; Yamazaki T.; Chayahara N.; Nakano K.; Inagaki L.; Toda K.; Enokida T.; Minami H.; Imamura Y.; Sasaki T.; Suzuki T.; Fujino K.; Dutcus C.E.; Takahashi S.; Lenvatinib for Anaplastic Thyroid Cancer. Front Oncol 2017,7,25","journal-title":"Front Oncol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","volume":"116","author":"Wan P.T.","year":"2004","unstructured":"Wan P.T.; Garnett M.J.; Roe S.M.; Lee S.; Niculescu-Duvaz D.; Good V.M.; Jones C.M.; Marshall C.J.; Springer C.J.; Barford D.; Marais R.; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004,116(6),855-867","journal-title":"Cell"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4161\/cc.6.3.3818","volume":"6","author":"Hou P.","year":"2007","unstructured":"Hou P.; Liu D.; Xing M.; Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 2007,6(3),377-379","journal-title":"Cell Cycle"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00428-005-1236-0","volume":"446","author":"Trovisco V.","year":"2005","unstructured":"Trovisco V.; Soares P.; Preto A.; de Castro I.V.; Lima J.; Castro P.; M\u00e1ximo V.; Botelho T.; Moreira S.; Meireles A.M.; Magalh\u00e3es J.; Abrosimov A.; Cameselle-Teijeiro J.; Sobrinho-Sim\u00f5es M.; Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients\u2019 age but not with tumour aggressiveness. Virchows Arch 2005,446(6),589-595","journal-title":"Virchows Arch"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1089\/thy.2015.0227","volume":"26","author":"Afkhami M.","year":"2016","unstructured":"Afkhami M.; Karunamurthy A.; Chiosea S.; Nikiforova M.N.; Seethala R.; Nikiforov Y.E.; Coyne C.; Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation. Thyroid 2016,26(2),242-247","journal-title":"Thyroid"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/path.1511","volume":"202","author":"Trovisco V.","year":"2004","unstructured":"Trovisco V.; Vieira de Castro I.; Soares P.; M\u00e1ximo V.; Silva P.; Magalh\u00e3es J.; Abrosimov A.; Guiu X.M.; Sobrinho-Sim\u00f5es M.; BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004,202(2),247-251","journal-title":"J Pathol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1172\/JCI23237","volume":"115","author":"Ciampi R.","year":"2005","unstructured":"Ciampi R.; Knauf J.A.; Kerler R.; Gandhi M.; Zhu Z.; Nikiforova M.N.; Rabes H.M.; Fagin J.A.; Nikiforov Y.E.; Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005,115(1),94-101","journal-title":"J Clin Invest"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1210\/jc.2003-030838","volume":"88","author":"Nikiforova M.N.","year":"2003","unstructured":"Nikiforova M.N.; Kimura E.T.; Gandhi M.; Biddinger P.W.; Knauf J.A.; Basolo F.; Zhu Z.; Giannini R.; Salvatore G.; Fusco A.; Santoro M.; Fagin J.A.; Nikiforov Y.E.; BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003,88(11),5399-5404","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/01.pas.0000176432.73455.1b","volume":"30","author":"Adeniran A.J.","year":"2006","unstructured":"Adeniran A.J.; Zhu Z.; Gandhi M.; Steward D.L.; Fidler J.P.; Giordano T.J.; Biddinger P.W.; Nikiforov Y.E.; Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006,30(2),216-222","journal-title":"Am J Surg Pathol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1365-2265.2006.02605.x","volume":"65","author":"Kim T.Y.","year":"2006","unstructured":"Kim T.Y.; Kim W.B.; Rhee Y.S.; Song J.Y.; Kim J.M.; Gong G.; Lee S.; Kim S.Y.; Kim S.C.; Hong S.J.; Shong Y.K.; The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006,65(3),364-368","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"Fagin J.A.","year":"2016","unstructured":"Fagin J.A.; Wells S.A.; Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med 2016,375(11),1054-1067","journal-title":"N Engl J Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/thy.2014.0123","volume":"25","author":"Falchook G.S.","year":"2015","unstructured":"Falchook G.S.; Millward M.; Hong D.; Naing A.; Piha-Paul S.; Waguespack S.G.; Cabanillas M.E.; Sherman S.I.; Ma B.; Curtis M.; Goodman V.; Kurzrock R.; BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 2015,25(1),71-77","journal-title":"Thyroid"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","volume":"17","author":"Brose M.S.","year":"2016","unstructured":"Brose M.S.; Cabanillas M.E.; Cohen E.E.; Wirth L.J.; Riehl T.; Yue H.; Sherman S.I.; Sherman E.J.; Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 2016,17(9),1272-1282","journal-title":"Lancet Oncol"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"6022","DOI":"10.1200\/JCO.2017.35.15_suppl.6022","volume":"35","author":"Manisha S.H.","year":"2017","unstructured":"Manisha S.H.; Wei L.; Wirth L.J.; Results of randomized phase 2 trial of dabrafenib versus dabrefenib plus trametinib in BRAF-mutated papillary thyroid carcinoma. J Clin Oncol 2017,35(15 suppl),6022-6022","journal-title":"J Clin Oncol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"Subbiah V.","year":"2018","unstructured":"Subbiah V.; Kreitman R.J.; Wainberg Z.A.; Cho J.Y.; Schellens J.H.M.; Soria J.C.; Wen P.Y.; Zielinski C.; Cabanillas M.E.; Urbanowitz G.; Mookerjee B.; Wang D.; Rangwala F.; Keam B.; Dabrafenib and Trametinib treatment in patients with locally advanced or metastatic BRAF B600-mutant anaplastic thyroid cancer. J Clin Oncol 2018,36(1),7-13","journal-title":"J Clin Oncol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1126\/science.1229259","volume":"339","author":"Huang F.W.","year":"2013","unstructured":"Huang F.W.; Hodis E.; Xu M.J.; Kryukov G.V.; Chin L.; Garraway L.A.; Highly recurrent TERT promoter mutations in human melanoma. Science 2013,339(6122),957-959","journal-title":"Science"},{"key":"ref=56","first-page":"2718","volume":"32","author":"Xing M.","year":"2014","unstructured":"Xing M.; Liu R.; Liu X.; BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014,32(25),2718-2726","journal-title":"J Clin Oncol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"E39","DOI":"10.3390\/genes7070039","volume":"7","author":"J\u00e4ger K.","year":"2016","unstructured":"J\u00e4ger K.; Walter M.; Therapeutic targeting of telomerase. Genes (Basel) 2016,7(7),E39","journal-title":"Genes (Basel)"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1210\/jc.2002-021222","volume":"88","author":"Teng L.","year":"2003","unstructured":"Teng L.; Specht M.C.; Barden C.B.; Fahey T.J.; III Antisense hTERT inhibits thyroid cancer cell growth. J Clin Endocrinol Metab 2003,88(3),1362-1366","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.mce.2017.03.007","volume":"448","author":"Maggisano V.","year":"2017","unstructured":"Maggisano V.; Celano M.; Lombardo G.E.; Lepore S.M.; Sponziello M.; Rosignolo F.; Verrienti A.; Baldan F.; Puxeddu E.; Durante C.; Filetti S.; Damante G.; Russo D.; Bulotta S.; Silencing of hTERT blocks growth and migration of anaplastic thyroid cancer cells. Mol Cell Endocrinol 2017,448,34-40","journal-title":"Mol Cell Endocrinol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev-med-042513-015127","volume":"66","author":"Rimawi M.F.","year":"2015","unstructured":"Rimawi M.F.; Schiff R.; Osborne C.K.; Targeting HER2 for the treatment of breast cancer. Annu Rev Med 2015,66,111-128","journal-title":"Annu Rev Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/2159-8290.CD-12-0531","volume":"3","author":"Montero-Conde C.","year":"2013","unstructured":"Montero-Conde C.; Ruiz-Llorente S.; Dominguez J.M.; Knauf J.A.; Viale A.; Sherman E.J.; Ryder M.; Ghossein R.A.; Rosen N.; Fagin J.A.; Relief of feedback inhibition of HER3 tanscription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov 2013,3(5),520-533","journal-title":"Cancer Discov"},{"key":"ref=62","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.76.3318","volume":"36","author":"Sherman EJ","year":"2018","unstructured":"Sherman EJ; Ho AL Fagin; JA Combination of dabrafenib (DAB) and lapatinib (LAP) for the treatment of BRAFmutant thyroid cancer. J Clin Oncol 2018,36(suppl;abstr 6087)","journal-title":"J Clin Oncol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1126\/science.289.5483.1357","volume":"289","author":"Kroll T.G.","year":"2000","unstructured":"Kroll T.G.; Sarraf P.; Pecciarini L.; Chen C.J.; Mueller E.; Spiegelman B.M.; Fletcher J.A.; PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected] Science 2000,289(5483),1357-1360","journal-title":"Science"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.mce.2009.10.013","volume":"321","author":"Eberhardt N.L.","year":"2010","unstructured":"Eberhardt N.L.; Grebe S.K.; McIver B.; Reddi H.V.; The role of the PAX8\/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol Cell Endocrinol 2010,321(1),50-56","journal-title":"Mol Cell Endocrinol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0002-9440(10)63902-8","volume":"162","author":"French C.A.","year":"2003","unstructured":"French C.A.; Alexander E.K.; Cibas E.S.; Nose V.; Laguette J.; Faquin W.; Garber J.; Moore F.; Fletcher J.A.; Larsen P.R.; Kroll T.G.; Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 2003,162(4),1053-1060","journal-title":"Am J Pathol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"4440","DOI":"10.1210\/jc.2002-021690","volume":"88","author":"Dwight T.","year":"2003","unstructured":"Dwight T.; Thoppe S.E.R.; Foukakis T.; Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Endorcinol Metabol 2003,88,4440-4445","journal-title":"Am J Endorcinol Metabol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"Article ID 672829","DOI":"10.1155\/2008\/672829","author":"Placzkowski K.A.","year":"2008","unstructured":"Placzkowski K.A.; Reddi H.V.; Grebe S.K.; Eberhardt N.L.; McIver B.; The role of the PAX8\/PPAR \u03b3 fusion oncogene in thyroid cancer. PPAR Res 2008,Article ID 672829","journal-title":"PPAR Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1471-2407-5-80","volume":"5","author":"Presta I.","year":"2005","unstructured":"Presta I.; Arturi F.; Ferretti E.; Mattei T.; Scarpelli D.; Tosi E.; Scipioni A.; Celano M.; Gulino A.; Filetti S.; Russo D.; Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene. BMC Cancer 2005,5,80","journal-title":"BMC Cancer"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.surg.2006.07.038","volume":"140","author":"Kebebew E.","year":"2006","unstructured":"Kebebew E.; Peng M.; Reiff E.; Treseler P.; Woeber K.A.; Clark O.H.; Greenspan F.S.; Lindsay S.; Duh Q.Y.; Morita E.; A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 2006,140(6),960-966","journal-title":"Surgery"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/thy.2008.0056","volume":"18","author":"Tepmongkol S.","year":"2008","unstructured":"Tepmongkol S.; Keelawat S.; Honsawek S.; Ruangvejvorachai P.; Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 2008,18(7),697-704","journal-title":"Thyroid"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1210\/jc.2017-02533","volume":"103","author":"Giordano T.J.","year":"2018","unstructured":"Giordano T.J.; Haugen B.R.; Sherman S.I.; Shah M.H.; Caoili E.M.; Koenig R.J.; Pioglitazone therapy of PAX8-PPAR\u03b3 Fusion protein thyroid carcinoma. J Clin Endocrinol Metab 2018,103(4),1277-1281","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1210\/er.2007-0007","volume":"28","author":"Xing M.","year":"2007","unstructured":"Xing M.; BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007,28(7),742-762","journal-title":"Endocr Rev"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1677\/erc.1.01119","volume":"13","author":"Riesco-Eizaguirre G.","year":"2006","unstructured":"Riesco-Eizaguirre G.; Guti\u00e9rrez-Mart\u00ednez P.; Garc\u00eda-Cabezas M.A.; Nistal M.; Santisteban P.; The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+\/I- targeting to the membrane. Endocr Relat Cancer 2006,13(1),257-269","journal-title":"Endocr Relat Cancer"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1530\/EJE-10-0290","volume":"163","author":"Barollo S.","year":"2010","unstructured":"Barollo S.; Pennelli G.; Vianello F.; Watutantrige Fernando S.; Negro I.; Merante Boschin I.; Pelizzo M.R.; Rugge M.; Mantero F.; Nacamulli D.; Girelli M.E.; Busnardo B.; Mian C.; BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol 2010,163(4),659-663","journal-title":"Eur J Endocrinol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1038\/sj.onc.1208822","volume":"24","author":"Giordano T.J.","year":"2005","unstructured":"Giordano T.J.; Kuick R.; Thomas D.G.; Misek D.E.; Vinco M.; Sanders D.; Zhu Z.; Ciampi R.; Roh M.; Shedden K.; Gauger P.; Doherty G.; Thompson N.W.; Hanash S.; Koenig R.J.; Nikiforov Y.E.; Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET\/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005,24(44),6646-6656","journal-title":"Oncogene"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1365-2265.2007.03008.x","volume":"68","author":"Mian C.","year":"2008","unstructured":"Mian C.; Barollo S.; Pennelli G.; Pavan N.; Rugge M.; Pelizzo M.R.; Mazzarotto R.; Casara D.; Nacamulli D.; Mantero F.; Opocher G.; Busnardo B.; Girelli M.E.; Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) 2008,68(1),108-116","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1210\/jc.2006-2707","volume":"92","author":"Durante C.","year":"2007","unstructured":"Durante C.; Puxeddu E.; Ferretti E.; Morisi R.; Moretti S.; Bruno R.; Barbi F.; Avenia N.; Scipioni A.; Verrienti A.; Tosi E.; Cavaliere A.; Gulino A.; Filetti S.; Russo D.; BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007,92(7),2840-2843","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=78","author":"Rothenberg SM","year":"2015","unstructured":"Rothenberg SM; McFadden DG; Palmer, EL Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib. Clin Cancer Res 1March; 21 (5), 1028-10352015","journal-title":"Clin Cancer Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1210\/js.2016-1114","volume":"1","author":"Huillard O.","year":"2017","unstructured":"Huillard O.; Tenenbaum F.; Clerc J.; Goldwasser F.; Groussin L.; Restoring radioiodine uptake in BRAF V600E-mutated papillary thyroid cancer. J Endocr Soc 2017,1(4),285-287","journal-title":"J Endocr Soc"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"Ho A.L.","year":"2013","unstructured":"Ho A.L.; Grewal R.K.; Leboeuf R.; Sherman E.J.; Pfister D.G.; Deandreis D.; Pentlow K.S.; Zanzonico P.B.; Haque S.; Gavane S.; Ghossein R.A.; Ricarte-Filho J.C.; Dom\u00ednguez J.M.; Shen R.; Tuttle R.M.; Larson S.M.; Fagin J.A.; Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013,368(7),623-632","journal-title":"N Engl J Med"},{"key":"ref=81","first-page":"287","volume":"4","author":"Tallini G.","year":"1998","unstructured":"Tallini G.; Santoro M.; Helie M.; Carlomagno F.; Salvatore G.; Chiappetta G.; Carcangiu M.L.; Fusco A.; RET\/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998,4(2),287-294","journal-title":"Clin Cancer Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1210\/en.2006-0921","volume":"148","author":"Ciampi R.","year":"2007","unstructured":"Ciampi R.; Nikiforov Y.E.; RET\/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007,148(3),936-941","journal-title":"Endocrinology"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"E916","DOI":"10.1210\/jc.2010-1599","volume":"96","author":"Sapio M.R.","year":"2011","unstructured":"Sapio M.R.; Guerra A.; Marotta V.; Campanile E.; Formisano R.; Deandrea M.; Motta M.; Limone P.P.; Fenzi G.; Rossi G.; Vitale M.; High growth rate of benign thyroid nodules bearing RET\/PTC rearrangements. J Clin Endocrinol Metab 2011,96(6),E916-E919","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1530\/EJE-11-0499","volume":"165","author":"Marotta V.","year":"2011","unstructured":"Marotta V.; Guerra A.; Sapio M.R.; Vitale M.; RET\/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur J Endocrinol 2011,165(4),499-507","journal-title":"Eur J Endocrinol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1158\/0008-5472.CAN-08-1982","volume":"69","author":"Castellone M.D.","year":"2009","unstructured":"Castellone M.D.; De Falco V.; Rao D.M.; Bellelli R.; Muthu M.; Basolo F.; Fusco A.; Gutkind J.S.; Santoro M.; The \u03b2-catenin axis integrates multiple signals downstream from RET\/papillary thyroid carcinoma leading to cell proliferation. Cancer Res 2009,69(5),1867-1876","journal-title":"Cancer Res"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/mc.20042","volume":"41","author":"Miyagi E.","year":"2004","unstructured":"Miyagi E.; Braga-Basaria M.; Hardy E.; Vasko V.; Burman K.D.; Jhiang S.; Saji M.; Ringel M.D.; Chronic expression of RET\/PTC 3 enhances basal and insulin-stimulated PI3 kinase\/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol Carcinog 2004,41(2),98-107","journal-title":"Mol Carcinog"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0027-5107(03)00056-3","volume":"527","author":"Saenko V.","year":"2003","unstructured":"Saenko V.; Rogounovitch T.; Shimizu-Yoshida Y.; Abrosimov A.; Lushnikov E.; Roumiantsev P.; Matsumoto N.; Nakashima M.; Meirmanov S.; Ohtsuru A.; Namba H.; Tsyb A.; Yamashita S.; Novel tumorigenic rearrangement, Delta rfp\/ret, in a papillary thyroid carcinoma from externally irradiated patient. Mutat Res 2003,527(1-2),81-90","journal-title":"Mutat Res"},{"key":"ref=88","first-page":"1093","volume":"6","author":"Rabes H.M.","year":"2000","unstructured":"Rabes H.M.; Demidchik E.P.; Sidorow J.D.; Lengfelder E.; Beimfohr C.; Hoelzel D.; Klugbauer S.; Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin Cancer Res 2000,6(3),1093-1103","journal-title":"Clin Cancer Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1089\/thy.2015.0673","volume":"26","author":"Opsahl E.M.","year":"2016","unstructured":"Opsahl E.M.; Brauckhoff M.; Schlichting E.; Helset K.; Svartberg J.; Brauckhoff K.; M\u00e6hle L.; Engebretsen L.F.; Sigstad E.; Gr\u00f8holt K.K.; Akslen L.A.; J\u00f8rgensen L.H.; Varhaug J.E.; Bj\u00f8ro T.; A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma. Thyroid 2016,26(9),1225-1238","journal-title":"Thyroid"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1210\/jc.2007-1714","volume":"93","author":"Elisei R.","year":"2008","unstructured":"Elisei R.; Cosci B.; Romei C.; Bottici V.; Renzini G.; Molinaro E.; Agate L.; Vivaldi A.; Faviana P.; Basolo F.; Miccoli P.; Berti P.; Pacini F.; Pinchera A.; Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008,93(3),682-687","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/annonc\/mdy188","volume":"29","author":"Seoane J.","year":"2018","unstructured":"Seoane J.; Capdevila J.; The right compound for the right target: tackling RET. Ann Oncol 2018,29(8),1623-1625","journal-title":"Ann Oncol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","volume":"8","author":"Subbiah V.","year":"2018","unstructured":"Subbiah V.; Gainor J.F.; Rahal R.; Brubaker J.D.; Kim J.L.; Maynard M.; Hu W.; Cao Q.; Sheets M.P.; Wilson D.; Wilson K.J.; DiPietro L.; Fleming P.; Palmer M.; Hu M.I.; Wirth L.; Brose M.S.; Ou S.I.; Taylor M.; Garralda E.; Miller S.; Wolf B.; Lengauer C.; Guzi T.; Evans E.K.; Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov 2018,8(7),836-849","journal-title":"Cancer Discov"},{"key":"ref=93","author":"Subbiah V.","year":"2018","unstructured":"Subbiah V.; Taylor M.; Lin J.; Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced, RET-altered solid tumors. AACR Annual Meeting Abstract CT043 Presented April 15, 2018.2018","journal-title":"AACR Annual Meeting Abstract CT043"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","volume":"29","author":"Subbiah V.","year":"2018","unstructured":"Subbiah V.; Velcheti V.; Tuch B.B.; Ebata K.; Busaidy N.L.; Cabanillas M.E.; Wirth L.J.; Stock S.; Smith S.; Lauriault V.; Corsi-Travali S.; Henry D.; Burkard M.; Hamor R.; Bouhana K.; Winski S.; Wallace R.D.; Hartley D.; Rhodes S.; Reddy M.; Brandhuber B.J.; Andrews S.; Rothenberg S.M.; Drilon A.; Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 2018,29(8),1869-1876","journal-title":"Ann Oncol"},{"key":"ref=95","volume":"36","author":"Drilon AE","year":"2018","unstructured":"Drilon AE; Subbiah V; Oxnard GR; A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. J Clin Oncol 2018,36(suppl; abstr 102)","journal-title":"J Clin Oncol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"10199","DOI":"10.1158\/0008-5472.CAN-04-4259","volume":"65","author":"Garc\u00eda-Rost\u00e1n G.","year":"2005","unstructured":"Garc\u00eda-Rost\u00e1n G.; Costa A.M.; Pereira-Castro I.; Salvatore G.; Hernandez R.; Hermsem M.J.; Herrero A.; Fusco A.; Cameselle-Teijeiro J.; Santoro M.; Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 2005,65(22),10199-10207","journal-title":"Cancer Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1210\/jc.2007-1717","volume":"93","author":"Abubaker J.","year":"2008","unstructured":"Abubaker J.; Jehan Z.; Bavi P.; Sultana M.; Al-Harbi S.; Ibrahim M.; Al-Nuaim A.; Ahmed M.; Amin T.; Al-Fehaily M.; Al-Sanea O.; Al-Dayel F.; Uddin S.; Al-Kuraya K.S.; Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008,93(2),611-618","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1210\/jc.2008-0273","volume":"93","author":"Liu Z.","year":"2008","unstructured":"Liu Z.; Hou P.; Ji M.; Guan H.; Studeman K.; Jensen K.; Vasko V.; El-Naggar A.K.; Xing M.; Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase\/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008,93(8),3106-3116","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1210\/jc.2016-2525","volume":"102","author":"Schneider T.C.","year":"2017","unstructured":"Schneider T.C.; de Wit D.; Links T.P.; Everolimus in patients with advanced follicular-derived thyroid cancer. J Clin Endocrinol Metab 2017,102(2),698-707","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=100","volume":"33","author":"Sherman EJ","year":"2015","unstructured":"Sherman EJ; Ho AL; Fury SS; Combination of everolimus and sorafenib in the treatment of thyroid cancer. Update of the phase II study J Clin Oncol 2015,33(suppl; abstr 6069)","journal-title":"Update of the phase II study J Clin Oncol"},{"key":"ref=101","first-page":"3455","volume":"54","author":"Reubi J.C.","year":"1994","unstructured":"Reubi J.C.; Schaer J.C.; Waser B.; Mengod G.; Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994,54(13),3455-3459","journal-title":"Cancer Res"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1158\/1078-0432.CCR-07-0935","volume":"13","author":"Iten F.","year":"2007","unstructured":"Iten F.; M\u00fcller B.; Schindler C.; Rochlitz C.; Oertli D.; M\u00e4cke H.R.; M\u00fcller-Brand J.; Walter M.A.; Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial. Clin Cancer Res 2007,13(22 Pt 1),6696-6702","journal-title":"Clin Cancer Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.semnuclmed.2016.01.010","volume":"46","author":"Salavati A.","year":"2016","unstructured":"Salavati A.; Puranik A.; Kulkarni H.R.; Budiawan H.; Baum R.P.; Peptide Receptor Radionuclide Therapy (PRRT) of medullary and no medullary thyroid cancer using radiolabeled somatostatin analogues. Semin Nucl Med 2016,46(3),215-224","journal-title":"Semin Nucl Med"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/eje.0.1460089","volume":"146","author":"Bl\u00e4ker M.","year":"2002","unstructured":"Bl\u00e4ker M.; de Weerth A.; Tometten M.; Schulz M.; H\u00f6ppner W.; Arlt D.; Hoang-Vu C.; Dralle H.; Terpe H.; Jonas L.; von Schrenck T.; Expression of the cholecystokinin 2-receptor in normal human thyroid gland and medullary thyroid carcinoma. Eur J Endocrinol 2002,146(1),89-96","journal-title":"Eur J Endocrinol"},{"key":"ref=105","volume":"56","author":"Rottenburger C","year":"2018","unstructured":"Rottenburger C; Nicolas G; McDougall L; Title evaluation of the CCK-2-receptor agonist 177Lu-PP-F1N for peptide receptor radionuclide therapy (PRRT) of medullary thyroid carcinoma \u2013 First results of a phase 0 \u2018Lumed\u2019 Study. Endoc Abstr 2018,56(GP234)","journal-title":"Endoc Abstr"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"Le D.T.","year":"2015","unstructured":"Le D.T.; Uram J.N.; Wang H.; Bartlett B.R.; Kemberling H.; Eyring A.D.; Skora A.D.; Luber B.S.; Azad N.S.; Laheru D.; Biedrzycki B.; Donehower R.C.; Zaheer A.; Fisher G.A.; Crocenzi T.S.; Lee J.J.; Duffy S.M.; Goldberg R.M.; de la Chapelle A.; Koshiji M.; Bhaijee F.; Huebner T.; Hruban R.H.; Wood L.D.; Cuka N.; Pardoll D.M.; Papadopoulos N.; Kinzler K.W.; Zhou S.; Cornish T.C.; Taube J.M.; Anders R.A.; Eshleman J.R.; Vogelstein B.; Diaz L.A.; PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015,372(26),2509-2520","journal-title":"N Engl J Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1530\/ERC-16-0421","volume":"24","author":"Ahn S.","year":"2017","unstructured":"Ahn S.; Kim T.H.; Kim S.W.; Ki C.S.; Jang H.W.; Kim J.S.; Kim J.H.; Choe J.H.; Shin J.H.; Hahn S.Y.; Oh Y.L.; Chung J.H.; Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer 2017,24(2),97-106","journal-title":"Endocr Relat Cancer"},{"key":"ref=108","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.6091","volume":"34","author":"Mehnert JM","year":"2016","unstructured":"Mehnert JM; Varga A; Marcia Brose, M Pembrolizumab for advanced papillary or follicular thyroid cancer: preliminary results from the phase 1b KEYNOTE-028 study. J Clin Oncol 2016,34(suppl; abstr 6091)","journal-title":"J Clin Oncol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1210\/jc.2015-4227","volume":"101","author":"Bastman J.J.","year":"2016","unstructured":"Bastman J.J.; Serracino H.S.; Zhu Y.; Koenig M.R.; Mateescu V.; Sams S.B.; Davies K.D.; Raeburn C.D.; McIntyre R.C.; Haugen B.R.; French J.D.; Tumor-Infiltrating T.; Cells and the PD-1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2016,101(7),2863-2873","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.6024","volume":"36","author":"Wirth LJ","year":"2018","unstructured":"Wirth LJ; Eigendorff E; Capdevila J; Phase I\/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with anaplastic thyroid cancer. J Clin Oncol 2018,36(suppl; abstr 6024)","journal-title":"J Clin Oncol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"Terme M.","year":"2013","unstructured":"Terme M.; Pernot S.; Marcheteau E.; Sandoval F.; Benhamouda N.; Colussi O.; Dubreuil O.; Carpentier A.F.; Tartour E.; Taieb J.; VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res 2013,73(2),539-549","journal-title":"Cancer Res"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1089\/thy.2014.0134","volume":"24","author":"Angell T.E.","year":"2014","unstructured":"Angell T.E.; Lechner M.G.; Jang J.K.; Correa A.J.; LoPresti J.S.; Epstein A.L.; BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. Thyroid 2014,24(9),1385-1393","journal-title":"Thyroid"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-018-0378-y","volume":"6","author":"Iyer P.C.","year":"2018","unstructured":"Iyer P.C.; Dadu R.; Gule-Monroe M.; Busaidy N.L.; Ferrarotto R.; Habra M.A.; Zafereo M.; Williams M.D.; Gunn G.B.; Grosu H.; Skinner H.D.; Sturgis E.M.; Gross N.; Cabanillas M.E.; Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer 2018,6(1),68","journal-title":"J Immunother Cancer"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179382","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/179382\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/179382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T16:57:32Z","timestamp":1608224252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179382\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":113,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2020,9,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200214125712","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-09-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}